Simcere Pharmaceutical Group Limited provided consolidated earnings guidance for the year ended December 31, 2023. The group will record a revenue of approximately RMB 6,578 million to RMB 6,638 million for the year ended December 31, 2023, representing an increase of approximately 4.0% to 5.0% as compared to the restated revenue of approximately RMB 6,324 million for the year ended December 31, 2022. The Group will record a profit attributable to equity shareholders of the company of approximately RMB 685 million to RMB 745 million for fiscal year 2023, representing a decrease of approximately 20.0% to 26.4% as compared to the restated profit attributable to equity shareholders of the company of approximately RMB 931 million for fiscal year 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.3 HKD | +1.15% | +2.91% | -21.25% |
Apr. 25 | Simcere Pharmaceutical’ Profit Down 23% in 2023 | MT |
Apr. 10 | Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-21.25% | 1.74B | |
+19.62% | 43.34B | |
+20.44% | 21.96B | |
+10.86% | 14.09B | |
+13.07% | 13.64B | |
+37.46% | 11.43B | |
-8.59% | 6.86B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+8.46% | 5.22B |
- Stock Market
- Equities
- 2096 Stock
- News Simcere Pharmaceutical Group Limited
- Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023